Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study
- PMID: 12089368
- DOI: 10.1097/01.asn.0000018407.60002.b9
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study
Abstract
This study sought to investigate the cardiac and renal effects of rigorous versus standard BP control on autosomal-dominant polycystic kidney disease (ADPKD). A prospective, randomized, 7-yr study was performed to examine the effect of rigorous (<120/80 mmHg) versus standard (135-140/85-90 mmHg) BP control on left ventricular mass index (LVMI) and kidney function in 75 hypertensive ADPKD patients with left ventricular hypertrophy. LVMI was measured by echocardiogram at baseline and at 1 and 7 yr. Renal function was assessed by measuring serum creatinine and 24-h creatinine clearance every 6 mo for 3 yr, then annually for an additional 4 yr. The baseline characteristics were comparable in the two groups. During the study, average mean arterial pressure was 90 +/- 5 mmHg for the rigorous group and 101 +/- 4 mmHg for the standard group (P < 0.0001). The LVMI decreased by 21% in the standard group and by 35% in the rigorous group. A mixed model longitudinal data analysis revealed that rigorous BP control was significantly more effective in decreasing LVMI (P < 0.01). There was no statistically significant difference in renal function between the two groups. In conclusion, left ventricular hypertrophy, a major cardiovascular risk factor, was decreased to a significantly greater extent by rigorous than standard BP control. This finding has particular clinical importance because cardiovascular complications are the most common cause of death in ADPKD patients.
Similar articles
-
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.Nephrol Dial Transplant. 2008 Feb;23(2):573-9. doi: 10.1093/ndt/gfm731. Epub 2007 Nov 4. Nephrol Dial Transplant. 2008. PMID: 17984104 Clinical Trial.
-
Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.Nephrol Dial Transplant. 1999 May;14(5):1113-6. doi: 10.1093/ndt/14.5.1113. Nephrol Dial Transplant. 1999. PMID: 10344347 Clinical Trial.
-
Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.Am J Kidney Dis. 2000 Mar;35(3):427-32. doi: 10.1016/s0272-6386(00)70195-8. Am J Kidney Dis. 2000. PMID: 10692268 Clinical Trial.
-
Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.J Am Soc Nephrol. 2009 Sep;20(9):1888-93. doi: 10.1681/ASN.2008080882. Epub 2009 Aug 20. J Am Soc Nephrol. 2009. PMID: 19696226 Review.
-
Cardiovascular complications in autosomal dominant polycystic kidney disease.Curr Hypertens Rev. 2013 Feb;9(1):2-11. doi: 10.2174/1573402111309010002. Curr Hypertens Rev. 2013. PMID: 23971638 Review.
Cited by
-
Early renal abnormalities in autosomal dominant polycystic kidney disease.Clin J Am Soc Nephrol. 2010 Jun;5(6):1091-8. doi: 10.2215/CJN.00360110. Epub 2010 Apr 22. Clin J Am Soc Nephrol. 2010. PMID: 20413443 Free PMC article.
-
Clinical burden of autosomal dominant polycystic kidney disease.Aging (Albany NY). 2020 Feb 24;12(4):3899-3910. doi: 10.18632/aging.102858. Epub 2020 Feb 24. Aging (Albany NY). 2020. PMID: 32096480 Free PMC article.
-
Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension.Kidney Int. 2008 Nov;74(9):1192-6. doi: 10.1038/ki.2008.397. Epub 2008 Aug 20. Kidney Int. 2008. PMID: 18716604 Free PMC article.
-
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.Cochrane Database Syst Rev. 2015 Jul 14;2015(7):CD010294. doi: 10.1002/14651858.CD010294.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2024 Oct 2;10:CD010294. doi: 10.1002/14651858.CD010294.pub3. PMID: 26171904 Free PMC article. Updated.
-
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3. Cochrane Database Syst Rev. 2024. PMID: 39356039
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical